Immunomediated Diseases and Innovative Therapies

< Back

Overview

The Immunomediated Diseases and Innovative Therapies is an heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, molecular diagnosis, heart repair, reumatology and advanced therapies. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

214
total
1,338.943
impact factor
6.257
average impact factor

Group Leader: Joan Sayós

group-team team group-zoom zoom group-download download

Research Areas

The main activity of our group this year has been related to develop a new project related with the molecular basis of hemophagocytic syndrome. Hemophagocytic syndrome (HLH) is a primary immunodeficiency produced by a combination of mutations in various genes and different triggers. In patients with primary HLH, bi-allelic mutations in genes of the cytolytic pathway are responsible for the onset of the disease in the absence of other factors. By contrast, in the secondary HLH patients, poorly characterized genetic defects seem to predispose to the disease, requiring additional stimuli such as viral infections, inflammatory or tumoral processes for the development of the same. During this year we have collected the HLH patient samples and performed their exome sequencing. Right now we are doing the analysis of the obtained sequences. On the other hand, we have developed the molecular and functional models that we are going to use to validate the impact of possible mutations on the function of cytotoxic cells and macrophages from HLH patients.

VHIR Annual Report 2018

© FIR-HUVH Fundació Institut de Recerca Hospital Universitari Vall d’Hebron 2019 | Developed by: ondeuev